• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The TRANSFORMS trial: Fingolimod vs interferon in multiple sclerosis [Classics Series]

byAndrew Cheung, MD MBA
July 31, 2013
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. Fingolimod significantly reduced the number of relapses as compared to interferon beta-1a over a one-year period.

2. Fingolimod was associated with more transient bradycardia and a higher infection rate as compared to interferon.

Original Date of Publication: February 4, 2010

Study Rundown: In summary, patients treated with fingolimod (1.25 mg or 0.5 mg) experienced significant lower annualized relapse rates as compared to those treated with interferon beta-1a in this phase 3 study (P<0.001 for both comparisons). These findings were supported by fingolimod patients having significantly fewer new or enlarging hyperintense lesions on T2-weighted magnetic resonance imaging than patients in the interferon group. The study also demonstrated dose-dependent increases in the incidence of bradycardia and atrioventricular block with fingolimod treatment. The one-year study duration limits assessment of the long-term safety and multiple sclerosis (MS) relapse outcomes, thus longer studies are needed. While it was hoped that oral medications for MS would improve compliance, this trial found higher rates of drug discontinuation with fingolimod, compared to interferon. Notably, the TRANSFORMS trial was supported by Novartis Pharma.

Please click to read study in NEJM

In-Depth [randomized, controlled study]: Originally published in 2010, the TRANSFORMS trial assessed the efficacy and safety of oral fingolimod, a sphingosine-1-phosphate-receptor modulator, compared to intramuscular interferon beta-1a in relapsing-remitting MS over a 12-month period. A total of 1,292 patients underwent randomization to receive fingolimod 1.25 mg daily, fingolimod 0.5 mg daily, or 30 µg of IM interferon beta-1a weekly.

RELATED REPORTS

The 2 Minute Medicine Podcast Episode 1

The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

The annualized relapse rates were 0.20 (95%CI 0.16-0.26) and 0.16 (95%CI 0.12- 0.21) for fingolimod 1.25 mg and 0.5 mg, respectively, compared to a rate of 0.33 (95%CI 0.26-0.42) for interferon beta-1a. The difference between fingolimod and interferon was significant (P<0.001) for both doses. A higher percentage of adverse events leading to drug discontinuation occurred in the high-dose fingolimod group, with a 10% discontinuation rate, versus 5.6% for the 0.5 mg fingolimod group and 3.7% for the interferon beta-1a group.

By Jose-Marc Techner, Andrew Cheung, M.D.

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain.

Tags: Fingolimodinterferonmultiple sclerosisTRANSFORMS
Previous Post

60% of food choking cases occur in children less than four years old

Next Post

Phase III trial shows survival benefit for early multiple myeloma

RelatedReports

2MM Podcast

The 2 Minute Medicine Podcast Episode 1

November 22, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: The Last Dance, Head of State, Trouble on the Farm and the Heart of COVID-19!

November 1, 2022
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Ublituximab lowers incidence of relapse and number of brain lesions in relapsing multiple sclerosis

August 26, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Next Post
Phase III trial shows survival benefit for early multiple myeloma

Phase III trial shows survival benefit for early multiple myeloma

Emerging coronavirus found to spread in healthcare facilities

MERS remains poorly understood, deadly

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options